NASDAQ:CBMGCellular Biomedicine Group Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cellular Biomedicine Group Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.00 -0.22 (-1.45 %) (As of 07/10/2020 03:39 PM ET) Add Compare Share Today's Range$14.91Now: $15.00▼$15.2550-Day Range$12.34MA: $14.24▼$16.6552-Week Range$10.98Now: $15.00▼$18.99Volume1,733 shsAverage Volume84,412 shsMarket Capitalization$290.85 millionP/E RatioN/ADividend YieldN/ABeta1.6 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases. The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase I clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a strategic licensing and collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingCellular Biomedicine Group has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.00, Cellular Biomedicine Group has a potential upside of 26.7% from its current price of $15.00.Amount of Analyst CoverageCellular Biomedicine Group has received no research coverage in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesCellular Biomedicine Group has received 190 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCellular Biomedicine Group has received 225 “underperform” votes. (Add your “underperform” vote.)Community SentimentCellular Biomedicine Group has received 54.22% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cellular Biomedicine Group and other stocks. Vote “Outperform” if you believe CBMG will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CBMG will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCellular Biomedicine Group does not currently pay a dividend.Dividend GrowthCellular Biomedicine Group does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cellular Biomedicine Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.50% of the stock of Cellular Biomedicine Group is held by insiders.Percentage Held by InstitutionsOnly 21.96% of the stock of Cellular Biomedicine Group is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cellular Biomedicine Group are expected to grow in the coming year, from ($2.80) to $0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cellular Biomedicine Group is -5.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cellular Biomedicine Group is -5.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCellular Biomedicine Group has a P/B Ratio of 5.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.19 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CBMG Previous Symbol CUSIPN/A CIK1378624 Webwww.cellbiomedgroup.com Phone347-905-5663Debt Debt-to-Equity RatioN/A Current Ratio1.00 Quick Ratio1.00Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$340,000.00 Price / Sales855.44 Cash FlowN/A Price / Cash FlowN/A Book Value$2.89 per share Price / Book5.19Profitability EPS (Most Recent Fiscal Year)($2.63) Net Income$-49,980,000.00 Net MarginsN/A Return on Equity-83.10% Return on Assets-51.14%Miscellaneous Employees193 Outstanding Shares19,390,000Market Cap$290.85 million Next Earnings Date8/4/2020 (Estimated) OptionableOptionable NASDAQ:CBMG Rates by TradingView Receive CBMG News and Ratings via Email Sign-up to receive the latest news and ratings for CBMG and its competitors with MarketBeat's FREE daily newsletter. Cellular Biomedicine Group (NASDAQ:CBMG) Frequently Asked Questions How has Cellular Biomedicine Group's stock been impacted by COVID-19 (Coronavirus)? Cellular Biomedicine Group's stock was trading at $14.49 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CBMG stock has increased by 3.5% and is now trading at $15.00. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Cellular Biomedicine Group? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellular Biomedicine Group in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cellular Biomedicine Group. When is Cellular Biomedicine Group's next earnings date? Cellular Biomedicine Group is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Cellular Biomedicine Group. How were Cellular Biomedicine Group's earnings last quarter? Cellular Biomedicine Group Inc (NASDAQ:CBMG) announced its earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.76) by $0.18. View Cellular Biomedicine Group's earnings history. What price target have analysts set for CBMG? 2 brokerages have issued twelve-month target prices for Cellular Biomedicine Group's stock. Their forecasts range from $19.00 to $19.00. On average, they anticipate Cellular Biomedicine Group's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 26.7% from the stock's current price. View analysts' price targets for Cellular Biomedicine Group. Has Cellular Biomedicine Group been receiving favorable news coverage? Press coverage about CBMG stock has been trending somewhat positive this week, InfoTrie reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cellular Biomedicine Group earned a daily sentiment score of 1.2 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Cellular Biomedicine Group. Are investors shorting Cellular Biomedicine Group? Cellular Biomedicine Group saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 328,200 shares, an increase of 9.3% from the June 15th total of 300,200 shares. Based on an average trading volume of 79,500 shares, the short-interest ratio is currently 4.1 days. Currently, 3.2% of the shares of the stock are short sold. View Cellular Biomedicine Group's Current Options Chain. Who are some of Cellular Biomedicine Group's key competitors? Some companies that are related to Cellular Biomedicine Group include Passage Bio (PASG), Translate Bio (TBIO), Compugen (CGEN), BioCryst Pharmaceuticals (BCRX), Atara Biotherapeutics (ATRA), Replimune Group (REPL), BAVARIAN NORDIC/S (BVNRY), Krystal Biotech (KRYS), Cellectis (CLLS), Vericel (VCEL), Osiris Therapeutics (OSIR), Agenus (AGEN), AVITA MED LTD/S (RCEL), Autolus Therapeutics (AUTL) and Proteon Therapeutics (PRTO). View all competitors. What other stocks do shareholders of Cellular Biomedicine Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cellular Biomedicine Group investors own include Crispr Therapeutics (CRSP), Anavex Life Sciences (AVXL), Aduro BioTech (ADRO), Amarin (AMRN), Adaptimmune Therapeutics (ADAP), Exelixis (EXEL), Fate Therapeutics (FATE), ImmunoGen (IMGN), Viewray (VRAY) and Agile Therapeutics (AGRX). Who are Cellular Biomedicine Group's key executives? Cellular Biomedicine Group's management team includes the following people: Mr. Bizuo Liu, CEO, CFO & Director (Age 54)Dr. Yihong Yao, Chief Scientific Officer (Age 51)Mr. Andrew K. Chan, Chief Legal Officer, Gen. Counsel, Sr. VP of Corp. Bus. Devel. & Sec. (Age 61)Dr. Li Zhang, Chief Production OfficerDerrick C. Li, Head of Strategy & Investor Relations What is Cellular Biomedicine Group's stock symbol? Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG." How do I buy shares of Cellular Biomedicine Group? Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cellular Biomedicine Group's stock price today? One share of CBMG stock can currently be purchased for approximately $15.00. How big of a company is Cellular Biomedicine Group? Cellular Biomedicine Group has a market capitalization of $290.85 million and generates $340,000.00 in revenue each year. The biotechnology company earns $-49,980,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Cellular Biomedicine Group employs 193 workers across the globe. What is Cellular Biomedicine Group's official website? The official website for Cellular Biomedicine Group is www.cellbiomedgroup.com. How can I contact Cellular Biomedicine Group? Cellular Biomedicine Group's mailing address is 1345 AVENUE OF AMERICAS 15TH FLOOR, NEW YORK NY, 10105. The biotechnology company can be reached via phone at 347-905-5663 or via email at [email protected] This page was last updated on 7/10/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
